Search Result for "Bladder Cancer"
Clinical Trial
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Clinical Trial
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Cancer Treatment
Bladder cancer treatment often includes surgery to remove a cancerous tumor. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our team regularly performs these complex procedures.
Our skilled genitourinary surgeons treat a very high number of patients, giving our team exceptional expertise. Some bladder surgery affects your body’s ability to urinate. Our surgeons perform reconstructive procedures to restore function. Many patients can urinate on their own after surgery, even without a bladder.
Clinical Trial
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Story
Bladder cancer is more aggressive and more advanced in South Texas residents than in many parts of the country, a study by the Mays Cancer Center indicates.
Story
According to the study, 53.4% of participants receiving NF were free of cancer at three months and 45.5% of patients continued to be cancer-free for at least 12 months.
Clinical Trial
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
Cancer Treatment
At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, you have access to care that is changing the way doctors detect and treat bladder cancer.
We are one of the regional centers of excellence in Texas offering blue light cystoscopy in the outpatient setting. This method enables our experts to more precisely detect and treat early-stage cancers that may otherwise go unnoticed.